Table 5 Completed and ongoing clinical trials evaluating the safety and efficacy of targeted drugs in patients with SCLC
From: Current and future therapies for small cell lung carcinoma
Study name | Trial number | Phase | Patients | Strategy | Drugs | N | ORR | Median OS | Median PFS | Safety (grade 3–4) |
|---|---|---|---|---|---|---|---|---|---|---|
SALUTE | NCT00403403 | 2 | ES-SCLC | chemo + anti-Angiogenesis | Chemo + bevacizumab vs. Chemo | 52 vs. 50 | 58% vs. 48% | 9.4 vs. 10.9 months | 5.5 vs. 4.4 months | 75% vs. 60% |
GOIRC-AIFA FARM6PMFJM | EudraCT number 2007-007949-13 | 3 | ES-SCLC | chemo + anti-Angiogenesis | Chemo + bevacizumab vs. Chemo | 101 vs. 103 | – | 9.8 vs. 8.9 months | 6.7 vs. 5.7 months | 6.3% vs. 1.0% |
ALTER1202 | NCT0305979 | 2 | Relapsed SCLC | Angiogenesis only | Anlotinib vs. Placebo | 67 vs. 34 | 4.5% vs. 3.9% | 7.3 vs. 4.4 months | 4.0 vs. 0.7 months | 51.9% vs. 34.6% |
– | NCT02038647 | 2 | Relapsed SCLC | Aurora Kinase A inhibitor + chemo | Paclitaxel + Alisertib vs. Paclitaxel | 89 vs. 89 | 22% vs. 18% | 6.11 vs. 5.42 months | 3.32 vs. 2.17 months | 67% vs. 22% |
– | NCT02499770 | 1b/2 | ES-SCLC | CDK4/6 inhibitor + chemo | Chemo + Trilaciclib vs. Chemo | 39 vs. 39 | 66.7% vs. 56.8% | 10.9 vs. 10.6 months | 6.2 vs.5.0 months | 50% vs. 83.8% |
– | NCT02289690 | 2 | ES-SCLC | PARP inhibitor + chemo | Chemo + Veliparib vs. Chemo | 61 vs. 61 | 77% vs. 64% | 10.1 bs 12.4 months | 5.8 vs. 5.6 months | 83% vs. 68% |
ECOG-ACRIN 2511 Study | NCT01642251 | 2 | ES-SCLC | PARP inhibitor + chemo | Chemo + Veliparib vs. Chemo | 64 vs. 64 | 71.9% vs. 65.6% | 10.3 vs. 8.9 months | 6.1 vs. 5.5 months | 49% vs. 32% |
– | NCT01901653 | 1 | Relapsed SCLC | ADC(DLL3) | Rova-T | 74 | 18% | 4.6 months | 3.1 months | – |
TAHOE | NCT03061812 | 3 | Second-Line | ADC(DLL3) | Rova-T vs. Topotecan | 296 vs. 148 | 15% vs. 21% | 6.3 vs. 8.6 months | 3.0 vs. 4.3 months | 64% vs. 88% |
MERU | NCT03033511 | 3 | ES-SCLC | ADC(DLL3) | Rova-T vs. Placebo | 372 vs. 376 | 9% vs. 4% | 8.8 vs. 9.9 months | 3.7 vs. 1.4 months | 59% vs. 30% |
– | NCT03319940 | 1 | Relapsed SCLC | TCE(DLL3) | Tarlatamab | 107 | 23.40% | 13.2 months | 3.7 months | – |
DeLLphi-301 | NCT05060016 | 2 | Relapsed SCLC | TCE(DLL3) | 10-mg Tarlatamab vs. 100-mg Tarlatamab | 88 vs. 88 | 40% vs. 32% | 14.3 vs. NE months | 4.9 vs. 3.9 months | 59% vs. 64% |